Group K Diagnostics (GKD) is developing a point-of-care diagnostic device, KromaHealth, that leverages paper-based microfluidics technology to reduce cost and time of testing for over 40 diseases. CEO and founder Brianna Wronko walks us through how she has translated her research at the University of Pennsylvania into a full fledged company that has raised $7 million to date. With the use of KromaHealth, she paints a picture of a more efficient doctor’s office visit devoid of the time lag between blood draw and lab result. For any diagnostic tool, the regulatory process can be daunting, so we go into the nuances of the 510(k) pathway for KromaHealth.